MedTrace Logo

A Study in Participants With Rheumatoid Arthritis

NCT01202773 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 456

Last updated 2018-05-14

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis in participants with an inadequate response to one or more tumor necrosis factor-alpha (TNF-α) inhibitors.

This study is comprised of 2 periods:

Period 1: 24-week blinded treatment

Period 2: 48-week post-treatment follow-up

Conditions

Interventions

DRUG

LY2127399

Administered Subcutaneously (SC)

DRUG

Placebo Q4W

Administered SC

DRUG

Placebo Q2W

Administered SC

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern Time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2013-03-31
Completion
2014-01-31

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Colombia
  • France
  • Germany
  • Greece
  • Italy
  • Japan
  • Malaysia
  • Mexico
  • New Zealand
  • Poland
  • Russia
  • South Africa
  • South Korea
  • Spain
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01202773 on ClinicalTrials.gov